BiotechTube

Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma, Newly Diagnosed

Conditions

Multiple Myeloma, Newly Diagnosed

Trial Timeline

Jul 9, 2025 → May 1, 2036

NCT ID
NCT06918002

About Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone

Elranatamab + Lenalidomide (Revlimid®) + Daratumumab SC (Darzalex) + Bortezomib (Velcade®) + Dexamethasone is a phase 3 stage product being developed by Pfizer for Multiple Myeloma, Newly Diagnosed. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06918002. Target conditions include Multiple Myeloma, Newly Diagnosed.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Myeloma, Newly Diagnosed were approved

Approved (20) Terminated (0) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
✅TeclistamabJohnson & JohnsonApproved
✅BortezomibJohnson & JohnsonApproved
✅DaratumumabJohnson & JohnsonApproved
✅Mavenclad®MerckApproved
✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06918002Phase 3Recruiting

Competing Products

20 competing products in Multiple Myeloma, Newly Diagnosed

See all competitors
ProductCompanyStageHype Score
mRNA-1195ModernaPhase 2
0
NEX-20ANanexa ABPhase 1
23
mRNA-2736ModernaPhase 1
0
mRNA-2808ModernaPhase 2
0
Placebo + PirtobrutinibEli LillyPhase 2
27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
32
agenT-797MiNK TherapeuticsPhase 1
19
Duloxetine Hydrochloride (HCI) + PlaceboEli LillyPhase 3
40
TemferonGenenta SciencePhase 1/2
14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
47
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
CS-0777 tablets + CS-0777 tablets + CS-0777 tabletsDaiichi SankyoPhase 1
29
ASP7487, Velcade, DexamethasoneAstellas PharmaPhase 1/2
24
PHE885NovartisPhase 2
27
Mirabegron + PlaceboAstellas PharmaApproved
43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved
43
Denileukin Diftitox (Ontak)EisaiPhase 1
21
PalonosetronEisaiPhase 2
35
BIW-8962Kyowa KirinPhase 1
21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)Kyowa KirinPhase 2
35